Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.
作者信息
Weisberg Ellen, Meng Chengcheng, Case Abigail, Sattler Martin, Tiv Hong L, Gokhale Prafulla C, Buhrlage Sara, Wang Jinhua, Gray Nathanael, Stone Richard, Liu Suiyang, Bhagwat Shripad V, Tiu Ramon V, Adamia Sophia, Griffin James D
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medicine, Harvard Medical School, Boston, MA, USA.
出版信息
Leukemia. 2020 Feb;34(2):625-629. doi: 10.1038/s41375-019-0552-3. Epub 2019 Aug 27.
Abstract
摘要
相似文献
1
Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.评估细胞外信号调节激酶作为急性髓性白血病的治疗靶点。
Leukemia. 2020 Feb;34(2):625-629. doi: 10.1038/s41375-019-0552-3. Epub 2019 Aug 27.
2
Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.更正：急性髓性白血病中ERK作为治疗靶点的评估。
Leukemia. 2020 Sep;34(9):2543. doi: 10.1038/s41375-020-0782-4.
3
Downmodulation of ERK activity inhibits the proliferation and induces the apoptosis of primary acute myelogenous leukemia blasts.细胞外信号调节激酶（ERK）活性的下调抑制原发性急性髓性白血病母细胞的增殖并诱导其凋亡。
Leukemia. 2003 Sep;17(9):1783-93. doi: 10.1038/sj.leu.2403032.
4
Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.一种Fc修饰的抗CD123抗体（CSL362）联合化疗在免疫缺陷小鼠急性髓性白血病异种移植模型中的疗效。
Haematologica. 2015 Jul;100(7):914-26. doi: 10.3324/haematol.2014.113092.
5
Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?是否存在化学诱导的BCR-ABL阳性慢性粒细胞白血病实体？
Oncologist. 2008 Jun;13(6):645-54. doi: 10.1634/theoncologist.2008-0057.
6
Acute myelogenous leukemia-derived SMAD4 mutations target the protein to ubiquitin-proteasome degradation.急性髓系白血病衍生的SMAD4突变将该蛋白靶向泛素-蛋白酶体降解。
Hum Mutat. 2006 Sep;27(9):897-905. doi: 10.1002/humu.20387.
7
8
WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.WT1在急性白血病、慢性粒细胞白血病和骨髓增生异常综合征中的作用：WT1靶向治疗的潜在疗效
Leukemia. 2003 Jul;17(7):1301-12. doi: 10.1038/sj.leu.2402988.
9
Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.阻断Raf/MEK/ERK信号通路可使急性髓性白血病细胞对洛伐他汀诱导的凋亡敏感。
Cancer Res. 2004 Sep 15;64(18):6461-8. doi: 10.1158/0008-5472.CAN-04-0866.
10
[Full-length cloning of a novel gene, ELF2C, related to familial acute myelogenous leukemia].[与家族性急性髓细胞白血病相关的新基因ELF2C的全长克隆]
Zhonghua Yi Xue Za Zhi. 2007 Aug 28;87(32):2245-8.
引用本文的文献
1
The MAP kinase negative regulator DUSP2 (dual specificity phosphatase 2) is controlled by oncogenic microRNA cluster miR-17-92, miR-106a-363 and miR-106b-25.丝裂原活化蛋白激酶负调控因子双特异性磷酸酶2（DUSP2）受致癌性微小RNA簇miR-17-92、miR-106a-363和miR-106b-25调控。
BMC Cancer. 2025 Jun 19;25(1):1020. doi: 10.1186/s12885-025-14434-z.
2
The roles of phosphorylation of signaling proteins in the prognosis of acute myeloid leukemia.信号蛋白磷酸化在急性髓系白血病预后中的作用。
Pathol Oncol Res. 2024 Jul 5;30:1611747. doi: 10.3389/pore.2024.1611747. eCollection 2024.
3
Exploring and clinical validation of prognostic significance and therapeutic implications of copper homeostasis-related gene dysregulation in acute myeloid leukemia.探讨铜稳态相关基因失调在急性髓系白血病中的预后意义和治疗意义，并进行临床验证。
Ann Hematol. 2024 Aug;103(8):2797-2826. doi: 10.1007/s00277-024-05841-6. Epub 2024 Jun 15.
4
Preclinical evaluation of the ROCK1 inhibitor, GSK269962A, in acute myeloid leukemia.ROCK1抑制剂GSK269962A在急性髓系白血病中的临床前评估
Front Pharmacol. 2022 Dec 6;13:1064470. doi: 10.3389/fphar.2022.1064470. eCollection 2022.
5
A somatic mutation in moesin drives progression into acute myeloid leukemia.一种驱动向急性髓系白血病进展的肌球蛋白结合蛋白基因突变。
Sci Adv. 2022 Apr 22;8(16):eabm9987. doi: 10.1126/sciadv.abm9987. Epub 2022 Apr 20.
6
Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.针对复发/难治性多发性骨髓瘤的 Erk1/2 和 CDK4/6i 联合治疗。
Leukemia. 2022 Apr;36(4):1088-1101. doi: 10.1038/s41375-021-01475-z. Epub 2022 Jan 27.
7
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.蛋白磷酸酶 2A 通过 c-Myc/p21 轴是人类和小鼠急性髓系白血病中具有治疗潜力的细胞命运决定的驱动因素。
Blood. 2022 Mar 3;139(9):1340-1358. doi: 10.1182/blood.2020010344.
8
Targeting in Cancer: Promising Therapeutic Strategies.癌症靶向治疗：有前景的治疗策略。
Cancers (Basel). 2021 Mar 10;13(6):1204. doi: 10.3390/cancers13061204.
9
ERK Inhibitor LY3214996-Based Treatment Strategies for -Driven Lung Cancer.基于 ERK 抑制剂 LY3214996 的治疗策略用于驱动型肺癌。
Mol Cancer Ther. 2021 Apr;20(4):641-654. doi: 10.1158/1535-7163.MCT-20-0531. Epub 2021 Feb 3.
10
TNFAIP8 promotes AML chemoresistance by activating ERK signaling pathway through interaction with Rac1.TNFAIP8 通过与 Rac1 相互作用激活 ERK 信号通路促进 AML 耐药性。
J Exp Clin Cancer Res. 2020 Aug 14;39(1):158. doi: 10.1186/s13046-020-01658-z.
Zotero 插件